Amgen Chief Executive Officer Robert Bradway is excited about 2022. During his presentation at the J.P. Morgan Healthcare Conference, Bradway said things are lining up for long-term growth for the California-based company.
The U.S. Food and Drug Administration approved Novartis’ Leqvio (inclisiran), the first small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (also known as bad cholesterol or LDL-C) with two doses a year, after an initial dose and one at three months.
Cambridge, Mass.-based Voyager Therapeutics entered a deal allowing Pfizer to exercise options to license novel capsids for gene therapies.
ProQR Therapeutics is collaborating with Indianapolis-based Eli Lilly to bolster the Dutch biotechnology company’s Axiomer RNA editing platform and create new medicines that could treat a range of genetic disorders.
Moderna Inc. completed the real-time review process needed for a full approval for the company’s Covid-19 vaccine in people aged 18 years and older.
International biopharmaceutical firm Genevant Sciences announced a global collaboration and licensing deal with Takeda Pharmaceutical to create and commercialize new therapies that would hopefully treat two undisclosed types of rare liver diseases.
An antiviral treatment under development by Atea Pharmaceuticals is showing promise against Covid-19.
Toronto-based biotech Deep Genomics landed $180 million in the company’s oversubscribed Series C.
A second-generation Covid-19 vaccine developed by CureVac and GlaxoSmithKline – designed to protect against coronavirus variants – produced a high level of immune response in a trial in rats, the companies said on May 13.
Eli Lilly will harness the power of MiNA Therapeutics’ proprietary small activating RNA (saRNA) technology platform to develop five novel drug candidates against diseases across the company’s core areas of focus.